Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient

AIDS

Volumn 25, Issue 18, 2011, Pages 2306-2308

  Wandeler, Gilles ^a   Furrer, Hansjakob ^a   Rauch, Andri ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EMTRICITABINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; CASE REPORT; CD4 LYMPHOCYTE COUNT; GENE MUTATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-2; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PYRROLIDINONES; RITONAVIR; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80855139786     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834cdb89     Document Type: Letter

References (12)

1. Gottlieb GS, Eholie SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:2069-2072; discussion 2073-2064.
2. Hansmann A, Schim van der Loeff MF, Kaye S, Awasana AA, Sarge-Njie R, O'Donovan D, et al. Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1-and HIV-2-infected women in a community-based cohort in The Gambia. J Acquir Immune Defic Syndr 2005; 38:335-341. (Pubitemid 40333501)
3. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, Coll-Seck AM, et al. Equal plasma viral loads predict a similar rate of CD4R T cell decline in human immunodeficiency virus (HIV) type 1-and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905-914. (Pubitemid 34274433)
4. Mullins C, Eisen G, Popper S, Dieng Sarr A, Sankale JL, Berger JJ, et al. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004; 38:1771-1779. (Pubitemid 38781672)
5. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459-462.
6. Trevino A, de Mendoza C, Caballero E, Rodriguez C, Parra P, Benito R, et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother 2011; 66:1484-1488.
7. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 2009; 48:476-483.
8. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22:1091-1092. (Pubitemid 351769751)
9. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22:665-666. (Pubitemid 351640604)
10. Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, Pillay D, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 2010; 86:224-226.
11. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914-920.
12. Gottlieb GS, Smith RA, Dia Badiane NM, Ba S, Hawes SE, Toure M, et al. HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS One 2011; 6:e22204.